4537-73-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyrimidinecarbothioamide (9CI) is used as a pharmaceutical intermediate for the synthesis of various therapeutic agents. Its unique chemical structure allows it to be a key component in the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Chemical Synthesis:
In the chemical industry, 2-Pyrimidinecarbothioamide (9CI) serves as a synthetic building block for the creation of more complex molecules. Its versatile structure can be modified and functionalized to produce a wide range of compounds with different properties and applications, making it a valuable asset in the development of new materials and chemicals.

InChI:InChI=1/C5H5N3S/c6-4(9)5-7-2-1-3-8-5/h1-3H,(H2,6,9)

Upstream product

• 14080-23-0 2-cyanopyrimidine 
• 62-55-5 thioacetamide 

Downstream Products

• 14080-23-0 2-cyanopyrimidine 
• 1322586-82-2 DB₁₈₃₁ 
• 1416850-62-8 4-methoxy-N-{4-[4-methoxy-2-(pyrimidin-2-yl)thiazol-5-yl]phenyl}-N-(4-methoxyphenyl)aniline 
• 1416850-61-7 4-[4-methoxy-2-(pyrimidin-2-yl)thiazol-5-yl]-N,N-di-p-tolylaniline 
• 1416850-55-9 4-[4-methoxy-2-(pyrimidin-2-yl)thiazol-5-yl]aniline 
• 1416850-51-5 C₁₄H₁₀N₄O₃S 
• 1416850-48-0 5-(4-nitrophenyl)-2-(pyrimidin-2-yl)thiazol-4-ol 

Relevant academic research and scientific papers

Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139

There remains an insufficient number of P2X7 receptor antagonists with adequate rodent potency, CNS permeability, and pharmacokinetic properties from which to evaluate CNS disease hypotheses preclinically. Herein, we describe the molecular pharmacology, s

Potent ribonucleotide reductase inhibitors: Thiazole-containing thiosemicarbazone derivatives

The antioxidant, antimalarial, antibacterial, and antitumor activities of thiosemicarbazones have made this class of compounds important for medicinal chemists. In addition, thiosemicarbazones are among the most potent and well-known ribonucleotide reductase inhibitors. In this study, 24 new thiosemicarbazone derivatives were synthesized, and the structures and purity of the compounds were determined by IR, 1H NMR, 13C NMR, mass spectroscopy, and elemental analysis. The IC50 values of these 24 compounds were determined with an assay for ribonucleotide reductase inhibition. Compounds 19, 20, and 24 inhibited ribonucleotide reductase enzyme activity at a higher level than metisazone as standard. The cytotoxic effects of these compounds were measured on the MCF7 (human breast adenocarcinoma) and HEK293 (human embryonic kidney) cell lines. Similarly, compounds 19, 20, and 24 had a selective effect on the MCF7 and HEK293 cell lines, killing more cancer cells than cisplatin as standard. The compounds (especially 19, 20, and 24 as the most active ones) were then subjected to docking experiments to identify the probable interactions between the ligands and the enzyme active site. The complex formation was shown qualitatively. The ADME (absorption, distribution, metabolism, and excretion) properties of the compounds were analyzed using in-silico techniques.

Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives

Steroidal and non-steroidal aromatase inhibitors target the suppression of estrogen biosynthesis in the treatment of breast cancer. Researchers have increasingly focused on developing non-steroidal derivatives for their potential clinical use avoiding steroidal side-effects. Non-steroidal derivatives generally have planar aromatic structures attached to the azole ring system. One part of this ring system comprises functional groups that inhibit aromatization through the coordination of the haem group of the aromatase enzyme. Replacement of the triazole ring system and development of aromatic/cyclic structures of the side chain can increase selectivity over aromatase enzyme inhibition. In this study, 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives were synthesized and physical analyses and structural determination studies were performed. The IC50 values were determined by a fluorescence-based aromatase inhibition assay and compound 1 (4-(2-hydroxyphenyl)-2-(pyrimidine-2-yl)thiazole) were found potent inhibitor of enzyme (IC50:0.42 nM). Then, their antiproliferative activity over MCF-7 and HEK-293 cell lines was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Compounds 1, 7, 8, 13, 15, 18, 21 were active against MCF-7 breast cancer cells. Lastly, a series of docking experiments were undertaken to analyze the crystal structure of human placental aromatase and identify the possible interactions between the most active structure and the active site.

INHIBITOR OF THE P2X7 RECEPTOR

The present invention provides (S)-N-(2-(4-chlorophenyl)-2-morpholinoethyl)-2- (pyrimidin-2-yl)-4-(trifluoromethyl)thiazole-5-carboxamide as P2X7 inhibitor, its use as a medicament, and a convenient enantiomeric synthesis protocol for the preparation of (

From liquid to solid-state fluorescence: Tricyclic lactones based on 4-hydroxy-1,3-thiazoles

This work describes the synthesis of a series of tricyclic lactones based on 4-hydroxy-1,3-thiazoles prepared by the classic Hantzsch synthesis. The tricyclic lactones are more rigid than the parent 4-hydroxythiazoles and are featured not only by fluorescence in solution, but also in the solid state. An extension of the chromophoric system was successfully realized by integration of the benzothiazole substructure, thus resulting in bathochromic shifts of absorption and also fluorescence. The new synthesized lactones additionally show interesting properties in solution, whereby the initial blue fluorescence changes dramatically with a variation of the pH value. Georg Thieme Verlag Stuttgart · New York.

Arylamine-modified thiazoles as donor-acceptor dyes: Quantum chemical evaluation of the charge-transfer process and testing as ligands in ruthenium(II) complexes

A series of new 4-hydroxy-1,3-thiazole-based chromophores bearing different arylamine components (triarylamines, carbazole, and phenothiazine) as electron donors and azaheterocycle components (pyridine, pyrazine and pyrimidine) as electron-acceptor moieti

5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS

5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly usef